News
Genable raises first round venture capital investment
1st September 2004
Genable Technologies, an early stage Irish biotechnology company, has raised €1.1 million in an investment round led by Delta Partners. Genable is developing gene-based therapies for the treatment of incurable inherited diseases. Its focus and world-leading position is in "dominant negative" diseases such as retinitis pigmentosa, which causes blindness. The company's technology platform provides for the suppression and replacement of genes. Developed from over 10 years of research, it is now entering into pre-clinical studies.
Genable adds industry experience to its board
6th October 2005
Genable Technologies Ltd, a bio-pharmaceutical company developing new gene medicines to treat inherited blindness, has appointed two directors to its board: Dr John Monahan, founder and former Chief Executive Officer of Avigen, Inc. (NASDAQ: AVGN); and, Dr Alan Boyd, former Research and Development Director of Ark Therapeutics Ltd (LSE: Ark).
